Samalizumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD200 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6542H10086N1702O2102S46 |
Molar mass | 147687.22 g·mol−1 |
(what is this?) (verify) |
Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1]
Samalizumab was developed by Alexion Pharmaceuticals.
References
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles with changed KEGG identifier
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- Monoclonal antibodies
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs